Advertisement

Topics

Sal. Oppenheim jr. & Cie. KGaA Company Profile

00:12 EST 19th December 2018 | BioPortfolio

Innovation and tradition – we have always succeeded in combining the two. Since the company‘s founding in 1789, the Cologne private bankers of Sal. Oppenheim have always been a motor for progress - open to new developments in industry and business, open to art and culture, and, of course, always open to new financial models. Sal. Oppenheim today is one of Europe‘s leading private banks. The focus of our activities is asset management and investment banking. Whether you are a wealthy private client or a demanding corporate customer, we completely adapt to your individual needs. Our independence guarantees the responsibility of our actions. It is the basis for our decisions and the foundation of our success: Sal. Oppenheim currently manages and administers € 123 billion of assets. Around 3.160 emloyees work at more than 20 sites in Germany and Europe. Our company‘s employees share one goal: your financial success

Location

Unter Sachsenhausen 4
Cologne
Berlin
D-50667
Germany

Contact

Phone: 49 (0)221 / 145-01
Fax: 49 (0)221 / 145-1512
Email: info@oppenheim.de


News Articles [247 Associated News Articles listed on BioPortfolio]

P&G completes acquisition of Merck KGaA’s OTC division

Procter & Gamble (P&G) has completed its acquisition of Merck KGaA’s Consumer Health business, in a move it hopes will help boost its flagging sales prospects. As part of the $4.2 billion d...

EC Okays Acquisition Of Merck KGaA's Consumer Health By Procter & Gamble

CINCINNATI (dpa-AFX) - The Darmstadt-based pharmaceutical company Merck KGaA (MKGAY.PK) said that it has received approval from the European Commission to sell its division for over-the-counter me...

docpharm KGaA - HV am 10.11.2018

- die ordentliche Hauptversammlung findet am Samstag, dem 10. November 2018 in den Räumen der Gesellschaft, docpharm KGaA, Greschbachstr. 7, 76229 Karlsruhe um 10:30 Uhr statt....

Physiomics’ annual revenue doubles thanks to lucrative Merck KGaA contract win

On top of the Merck KGaA win, Physiomics inked deals with several other pharma and biotech groups last year

docpharm KGaA - HV am 21.07.2018

- die ordentliche Hauptversammlung findet am Samstag, dem 21. Juli 2018 in den Räumen der Gesellschaft, docpharm KGaA, Greschbachstr. 7, 76229 Karlsruhe um 10:30 Uhr statt....

Merck KGaA zuversichtlich, Analyst mit Kaufempfehlung: Aktie nimmt Kurs auf Widerstand

Der DAX-Konzern Merck KGaA will sein schwächelndes Geschäft mit Spezialmaterialien auf den Wachstumskurs zurückbringen. Der Unternehmensbereich bündelt das Spezialchemikaliengeschäft von Merck un...

AKTIE IM FOKUS 2: Merck KGaA drehen ins Plus - Warburg: starkes Wachstum

(neu: Aktienkurs, mehr Details) FRANKFURT (dpa-AFX Broker) - Nach Kursverlusten in der ersten Handelsstunde haben die Aktien der Merck KGaA ins Plus gedreht und die Gewinne ausgebaut. Sie legten z...

William Oppenheim, M.D., Director of the Cerebral Palsy Program at Orthopaedic Institute for Children, Honored by the American Academy of Pediatrics

William L. Oppenheim, M.D., director of the Cerebral Palsy Program at Orthopaedic Institute for Children (OIC) and director of the UCLA/Orthopaedic Hospital Center for Cerebral Pa...

Drugs and Medications [2 Associated Drugs and Medications listed on BioPortfolio]

Prenate essential [Sciele Pharma, Inc.]

Prenate Essential™ Rx prenatal vitamin & DHA

Prenate elite [Shionogi Pharma, Inc.]

PRENATE ELITE Tablets Rx

PubMed Articles [3 Associated PubMed Articles listed on BioPortfolio]

Automated small-scale in vitro transfer model as screening tool for the prediction of in vivo-dissolution and precipitation of poorly solubles.

Precipitation testing, especially for weakly basic APIs, represents a key parameter in drug substance characterization during early development stages, where the amount of API available is limited. Th...

PD-L1 immunostaining scoring for non-small cell lung cancer based on immunosurveillance parameters.

Non-Small Cell Lung Cancer (NSCLC) is the leading cause of cancer death globally, and new immunotherapies developed and under development targeting PD-1/PD-L1 checkpoint inhibition require accurate pa...

Patient Power Revolution in Multiple Sclerosis: Navigating the New Frontier.

A debate on shared decision making in multiple sclerosis (MS) was led by a patient advocate and leading neurologists from the MS in the 21st Century Steering Group. Key themes and salient points whic...

Clinical Trials [3 Associated Clinical Trials listed on BioPortfolio]

Fasting Bioequivalence Study of Memantinol 20 mg Tablets Versus Akatinol Memantine® 20 mg Tablets In Normal Healthy Subjects

This study are two-way crossover, open-label, single-dose, fasting, bioequivalence study of Memantinol® (JSC "GEROPHARM", Russia) 20 mg tablets versus Akatinol Memantine® (Merz Pharma Gm...

Study of EMD531444 in Subjects With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy

Darmstadt, Germany, June 17 2010 - Merck Serono, a division of Merck KGaA, and its U.S. affiliate, EMD Serono, Inc. today announced that they are resuming their Stimuvax® (BLP25 liposome ...

EMD 525797 in Colorectal & Ovarian Cancer Patients With Liver Metastases

This study is intended to test an experimental drug called EMD 525797 (Study Drug). This drug is not yet approved for sale and has only been tested in a small number of people to date (pri...

Companies [30 Associated Companies listed on BioPortfolio]

Sal. Oppenheim jr. & Cie. KGaA

Innovation and tradition – we have always succeeded in combining the two. Since the company‘s founding in 1789, the Cologne private bankers of Sal. Oppenheim have always been a motor for progress ...

Oppenheim Pramerica Fonds Trust GmbH

Nil

Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 40,000 employees work to further develop ...

Alphapharm

Alphapharm is one of Australia's leading pharmaceutical companies. We develop, manufacture, market and distribute prescription medicines and medicines only available at pharmacies. Our speciality is b...

EMD Biosciences, Inc

Together EMD Biosciences and Merck Biosciences are the research reagents group of the Life Science Products division of Merck KGaA. Merck KGaA was founded in 1668 in Darmstadt, Germany, and now has mo...

More Information about "Sal. Oppenheim jr. & Cie. KGaA" on BioPortfolio

We have published hundreds of Sal. Oppenheim jr. & Cie. KGaA news stories on BioPortfolio along with dozens of Sal. Oppenheim jr. & Cie. KGaA Clinical Trials and PubMed Articles about Sal. Oppenheim jr. & Cie. KGaA for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Sal. Oppenheim jr. & Cie. KGaA Companies in our database. You can also find out about relevant Sal. Oppenheim jr. & Cie. KGaA Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record